SMOLDERING PLASMA CELL MYELOMA
Clinical trials for SMOLDERING PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new SMOLDERING PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for SMOLDERING PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a cancer immunotherapy drug delay or stop smoldering myeloma?
Disease control OngoingThis early-phase trial tested the immunotherapy drug pembrolizumab in 20 adults with smoldering multiple myeloma at intermediate or high risk of progressing to active disease. The goal was to see if the drug could shrink or control the cancer and delay progression. Participants r…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Can an arthritis drug slow down multiple myeloma?
Disease control OngoingThis very early trial tested leflunomide, an anti-inflammatory drug, in just one person with high-risk smoldering multiple myeloma. The goal was to see if the drug could delay the disease from becoming active myeloma. The study focused on safety and whether the drug slows progres…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Could an immune-suppressing drug stall multiple myeloma before it starts?
Disease control OngoingThis study tests leflunomide, a drug that lowers immune activity, in 27 African-American and European-American adults with high-risk smoldering multiple myeloma. The goal is to see if it can delay the disease from turning into active multiple myeloma. Participants take the drug a…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for high-risk myeloma: drug combo aims to stop cancer before it starts
Disease control OngoingThis study tests a drug called isatuximab, given alone or with lenalidomide, in people with a high-risk form of smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the disease and delay progression to active myeloma. About 61 participants are en…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC